Follow the registration Link for Fee details

The mission of our conference is to understand the issues surrounding early diagnosis of lung cancer, how to optimize early treatment, and to expand practice-relevant research to medical and scientific communities in the U.S. and abroad.  The Early Lung Cancer Action Program (ELCAP) screening effort began in 1992 and evolved into the International Early Lung Cancer Action Program (I-ELCAP).  By providing training and the ELCAP Management System to those interested in screening, such programs expanded worldwide.  The resulting data and analyses from these sites provide new diagnostic knowledge that is integrated into the continually updated screening regimen so that it remains state-of-the-art; and screening advances are addressed at every conference.  In addition, The Early Lung Cancer Research on Treatment (IELCART) study uses the power of the prospective cohort design to accumulate data on clinical care treatment, similar in design to the I-ELCAP cohort.  That data analysis is used to address questions efficiently about stage I lung cancer treatments.  The IELCART research goal is to maximize the benefit of screening by determining optimal treatments when disease is discovered.  And finally, the newest focus of research at this conference is on interstitial lung disease (ILD).  Following the same research paradigms as I-ELCAP & IELCART we have developed an ILD registry and are recruiting collaborating sites. 

Tuesday, October 16^th

8:00 – 9:00                Registration/Continental Breakfast 

9:00 – 9:45                Conference Welcome. J. P. Smith, I-ELCAP Advisory Board

                                    Program Overview. C. Henschke

I-ELCAP and IELCART Update. C. Henschke

                                   

  9:45 – 11:00              Global Updates of Screening Initiatives. Moderator: C. Connery

 9:45 – 10:00   A High Risk Lung Cancer Screening Program: The Canadian Way. H. Schmidt

10:00 – 10:15  Initiatives in China. W. Tang

10:15 – 10:30  Poland and Eastern Europe. W. Rzyman

10:30 – 10:45  Screening in Brazil. R. Sales dos Santos

10:45 – 11:00 IASLC Lung Cancer Screening Initiative. J. Mulshine

 

11:00 – 11:15              COFFEE BREAK

 

11:15– 12:30              Stage I Lung Cancer. Moderator: F. Grannis

11:15 – 11:30  Surgical morbidity and mortality for Stage I lung cancer in CALGB. N. Altorki

11:30 – 11:45  Surgical morbidity and mortality in Stage I lung cancer in IELCART. D. Nicastri

11:45 – 12:00  Radiotherapy for Stage I. K. Rosenzweig

12:00 – 12:15  Sentinel lymph nodes in Stage I. M. Quereshi

12:15 – 12:30  Tumor microenvironment and prognoses.  H. Pass

 

12:30 – 1:30                LUNCH

                                       

1:30 – 2:30                  Preliminary findings from IELCART. Moderator: H. Pass

1:30 – 1:45      Why the robot?            C. Connery

1:45 – 2:00      Why not? R. Flores

2:00 – 2:15      What drives decisions in IELCART. R. Yip

2:15 – 2:30      Role of FNA in IELCART. D. Yankelevitz

 

2:30 – 3:30                  Aggressiveness of Stage I Lung Cancer Moderator: D. Yankelevitz

2:30 – 2:45      Size, grade, histology what do we know? E. Burks

2:45 – 3:00      Biomarkers. F. Hirsch

3:00 – 3:15      Tumor doubling times, PET scans and prognosis. Y. Wang

3:15 – 3:30      Molecular characterization and prognosis. L. Montuenga

 

Tuesday, October 16^th (continued)

 

3:30 – 4:00                  COFFEE BREAK

 

4:00 – 4:45                  Panel Discussion of Difficult Cases. Moderator: T. Collins

                                    Panel members:  H. Suseelan, M. Salvatore, L. DiFabrizio, R. Flores, C. Connery

 

4:45 – 5:45                  Closed Meeting for I-ELCAP and IELCART Members

 

6:00 – 9:00                  CONFERENCE DINNER – Culinary Institute of America

 

e   f

 

Wednesday, October 17^th

8:00 – 9:00                Registration/Continental Breakfast 

9:00 – 10:15                Screening updates. Moderator: J. Mulshine, J. Fields

9:00 – 9:15      Quantitative Screening Report. A. Reeves

9:15 – 9:30      Why are we not performing more screening? A. McKee

9:30 – 9:45      Nodule growth? D. Yankelevitz

9:45 – 10:00    Low-dose radiation. R. Subramaniam

10:00 – 10:15  Efficiency of ACR-LungRADS and I-ELCAP. C. Henschke

 

10:15 – 10:45              COFFEE BREAK

 

10:45 – 11:30              New Horizons. Moderator: J. Mulshine

10:45 – 11:00  Where will improved image quality take us. R. Avila

11:00 – 11:15  Lessons learned from social media. V. Krishnamurthy

11:15 – 11:30  Using AI for outreach to smokers. A. Ramos

 

11:30 – 12:30              Heart Disease and CT screening. Moderator: K. Haleem

11:30 – 11:45  Does heart size matter and how to measure it? J. Ling

11:45 – 12:00  Coronary artery disease in high-performance athletes. K. Haleem

12:00 – 12:15  Coronary contrast CT approaches.  M. Yen

12:15 – 12:30 Aortic aneurysms and monitoring. A Messina

 

12:30 – 1:15                LUNCH

 

1:15 – 2:15                  Health Check. Moderator: D. Yankelevitz

1:15 – 1:30      Why the distinction between cancer screening and health check? L. Fenton

1:30 – 1:45      Title TBD. A. McGlothlin

1:45 – 2:00      Implications of aortic valve calcifications. Y. Zhu

2:00 – 2:15      Reporting ancillary findings and legal considerations. L. Goldsmith

 

2:15 – 3:15                  Update on VA-PALS. Moderator: C. Henschke

2:15 – 2:30      Update on VA-PALS and VALOR. D. Moghanaki

2:30 – 2:45      Implementation at the Phoenix VA. S. Aguayo

2:45 – 3:00      Development of VA QA for screening. D. Yankelevitz

3:00 – 3:15      Implementation Assessment. J. Lewis, L Spalluto

 

3:15 – 4:00                  Interstitial Lung Disease. Moderator: T. Collins

3:15 – 3:30      ILD in the community setting. H. Suseelan

3:30 – 3:45      Meta-analysis of ILD and lung cancer. M. Salvatore

3:45 – 4:00      Next generation treatments for ILD and monitoring them        . M. Padilla